Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

CagriSema vs Liraglutide

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Liraglutide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

CagriSema

Phase 3

Liraglutide

FDA-Approved

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

CagriSema Liraglutide
Class Amylin + GLP-1 combination GLP-1 receptor agonist
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Dual amylin + GLP-1 receptor agonism GLP-1R agonist; albumin-binding fatty acid extends half-life
Route SC injection SC injection
Half-life ~7 days ~13 hrs
Dosage (research) 2.4 mg / 2.4 mg SC weekly 0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label)
Evidence tier Phase 3 FDA-Approved
Research depth 113 indexed (PubMed 49 · CT 32 · EPMC 32) 321 indexed (PubMed 197 · CT 69 · EPMC 55)
Availability Investigational Prescription
Reported risks GI effects; Phase 3 REDEFINE mixed results Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick CagriSema or Liraglutide?

Liraglutide has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between CagriSema and Liraglutide?

CagriSema is classed as Amylin + GLP-1 combination; Liraglutide is classed as GLP-1 receptor agonist. Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Liraglutide, GLP-1R agonist; albumin-binding fatty acid extends half-life. Reported half-life: CagriSema, ~7 days; Liraglutide, ~13 hrs. Routes in published studies: CagriSema, SC injection; Liraglutide, SC injection.

Which has stronger evidence, CagriSema or Liraglutide?

Liraglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Liraglutide is graded FDA-Approved, with 64 cited sources on its reference page and 321 indexed studies.

Which is more accessible, CagriSema or Liraglutide?

Liraglutide is FDA-approved and CagriSema is not. Catalog status: CagriSema, Investigational; Liraglutide, Prescription.

Are CagriSema and Liraglutide ever combined?

CagriSema and Liraglutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…